About: Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea
Creator	Cosgriff, Thomas Pittman, Philip Huggins, John Boudreau, Ellen Byrne, William Chung, Kyung Erlichman, Marianne Gibbs, Paul Kim, Katie Kim, Theodore Rezvani, David Rusnak, Janice
source	Elsevier; Medline; PMC
abstract	Abstract Results of a clinical study using intravenous (IV) ribavirin for treating Department of Defense personnel with hemorrhagic fever with renal syndrome (HFRS) acquired in Korea from 1987 to 2005 were reviewed to determine the clinical course of HFRS treated with IV ribavirin. A total of 38 individuals enrolled in the study had subsequent serological confirmation of HFRS. Four of the 38 individuals received three or fewer doses of ribavirin and were excluded from treatment analysis. Of the remaining 34 individuals, oliguria was present in one individual at treatment initiation; none of the remaining 33 subjects developed oliguria or required dialysis. The mean peak serum creatinine was 3.46mg/dl and occurred on day 2 of ribavirin therapy. Both the peak serum creatinine and the onset of polyuria occurred on mean day 6.8 of illness. Reversible hemolytic anemia was the main adverse event of ribavirin, with a ≥25% decrease in hematocrit observed in 26/34 (76.5%) individuals. While inability to adjust for all baseline variables prevents comparison to historical cohorts in Korea where oliguria has been reported in 39–69% cases and dialysis required in approximately 40% HFRS cases caused by Hantaan virus, the occurrence of 3% oliguria and 0% dialysis requirement in the treatment cohort is supportive of a previous placebo-controlled HFRS trial in China where IV ribavirin given early resulted in decreased occurrence of oliguria and decreased severity of renal insufficiency.
has issue date	2009-01-31(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2008.09.007
bibo:pmid	18977392
has license	els-covid
sha1sum (hex)	23dade1e22f513bf2a5375a1aa7c45da363dcdef
schema:url	https://doi.org/10.1016/j.antiviral.2008.09.007
resource representing a document's title	Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea
has PubMed Central identifier	PMC7127354
has PubMed identifier	18977392
schema:publication	Antiviral Research
resource representing a document's body	covid:23dade1e22f513bf2a5375a1aa7c45da363dcdef#body_text
is schema:about of	named entity 'renal' named entity 'virus' named entity 'observed' named entity 'excluded' named entity 'oliguria' named entity 'ribavirin' named entity 'hemorrhagic fever' named entity 'CHINA' named entity 'REVIEWED' named entity 'INABILITY' named entity 'TREATMENT' named entity 'MEAN' named entity 'MG%' named entity 'PRESENT' named entity 'THERAPY' named entity 'USING' named entity 'HFRS' named entity 'OCCURRED' named entity 'REVERSIBLE' named entity 'GIVEN' named entity 'CONFIRMATION OF' named entity 'DECREASED' named entity 'INDIVIDUAL' named entity 'ANALYSIS' named entity 'OCCURRENCE' named entity 'OLIGURIA' named entity 'PLACEBO-CONTROLLED' covid:arg/23dade1e22f513bf2a5375a1aa7c45da363dcdef named entity 'DETERMINE' named entity 'VARIABLES' named entity 'DECREASED OCCURRENCE' named entity '40%' named entity 'REPORTED' named entity 'COMPARISON' named entity 'REMAINING' named entity 'HISTORICAL' named entity 'INDIVIDUALS' named entity 'HEMATOCRIT' named entity 'ONSET OF' named entity 'HEMORRHAGIC FEVER WITH RENAL SYNDROME' named entity 'TO ADJUST' named entity 'SUPPORTIVE' named entity 'BASELINE' named entity 'SEVERITY' named entity 'STUDY' named entity 'HEMOLYTIC ANEMIA' named entity 'INTRAVENOUS' named entity 'PREVENTS' named entity 'DECREASE' named entity 'EARLY' named entity 'RENAL INSUFFICIENCY' named entity 'ILLNESS' named entity 'RESULTS' named entity 'CAUSED BY' named entity 'DEPARTMENT OF DEFENSE' named entity 'SERUM CREATININE' named entity 'APPROXIMATELY' named entity 'TRIAL' named entity 'KOREA' named entity 'ADVERSE EVENT' named entity 'THE PEAK' named entity 'MAIN' named entity 'REQUIRED' named entity 'COHORTS' named entity 'KOREA' named entity 'SUBJECTS' named entity 'RIBAVIRIN' named entity 'DAY 6' named entity 'COHORT' named entity 'SUBSEQUENT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software